title: Antifungal Activity of Brazilian Propolis Microparticles against Yeasts Isolated from Vulvovaginal Candidiasis.
abstract: Propolis, a resinous compound produced by Apis mellifera L. bees, is known to possess a variety of biological activities and is applied in the therapy of various infectious diseases. The aim of this study was to evaluate the in vitro antifungal activity of propolis ethanol extract (PE) and propolis microparticles (PMs) obtained from a sample of Brazilian propolis against clinical yeast isolates of importance in the vulvovaginal candidiasis (VVC). PE was used to prepare the microparticles. Yeast isolates (n = 89), obtained from vaginal exudates of patients with VVC, were exposed to the PE and the PMs. Moreover, the main antifungal drugs used in the treatment of VVC (Fluconazole, Voriconazole, Itraconazole, Ketoconazole, Miconazole and Amphotericin B) were also tested. Minimum inhibitory concentration (MIC) was determined according to the standard broth microdilution method. Some Candida albicans isolates showed resistance or dose-dependent susceptibility for the azolic drugs and Amphotericin B. Non-C. albicans isolates showed more resistance and dose-dependent susceptibility for the azolic drugs than C. albicans. However, all of them were sensitive or dose-dependent susceptible for Amphotericin B. All yeasts were inhibited by PE and PMs, with small variation, independent of the species of yeast. The overall results provided important information for the potential application of PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.
authors: Graduate Program of Health Sciences, State University of Maringa, Parana, Brazil.
authors: Kelen Fátima Dalben
authors: KF
authors: Dota
authors: Marcia Edilaine Lopes
authors: ME
authors: Consolaro
authors: Terezinha Inez Estivalet
authors: TI
authors: Svidzinski
authors: Marcos Luciano
authors: ML
authors: Bruschi
references: Int J Gynaecol Obstet. 2005 May;89(2):127-32
references: 15847875
references: Evid Based Complement Alternat Med. 2009 Dec;6(4):483-7
references: 18955250
references: J Pharm Sci. 2007 Aug;96(8):2074-89
references: 17301966
references: Rev Iberoam Micol. 2004 Dec;21(4):202-5
references: 15709802
references: J Infect Chemother. 2008 Apr;14(2):77-85
references: 18622668
references: Evid Based Complement Alternat Med. 2005 Mar;2(1):33-38
references: 15841276
references: Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):820-3
references: 7573250
references: J Pharm Pharmacol. 2009 Jan;61(1):41-6
references: 19126295
references: Food Chem Toxicol. 1998 Apr;36(4):347-63
references: 9651052
references: Mem Inst Oswaldo Cruz. 2006 Aug;101(5):493-7
references: 17072451
references: Int J Antimicrob Agents. 2005 Nov;26(5):343-56
references: 16323269
references: Mycopathologia. 2004 Feb;157(2):163-9
references: 15119851
references: Lancet. 2002 Mar 30;359(9312):1135-44
references: 11943280
references: J Med Vet Mycol. 1996 Sep-Oct;34(5):337-9
references: 8912167
references: J Ethnopharmacol. 2005 Dec 1;102(3):371-6
references: 16084044
references: Clin Microbiol Rev. 1999 Oct;12(4):501-17
references: 10515900
references: Mycopathologia. 2005 Jun;159(4):501-7
references: 15983735
references: J Clin Microbiol. 2008 May;46(5):1793-803
references: 18337384
references: Mycoses. 2001 Nov;44(9-10):375-8
references: 11766101
references: Lancet. 2007 Jun 9;369(9577):1961-71
references: 17560449
references: Evid Based Complement Alternat Med. 2008 Sep;5(3):317-24
references: 18830454
references: Planta Med. 2006 Aug;72(10):899-906
references: 16902858
references: Int J Pharm. 2003 Oct 2;264(1-2):45-55
references: 12972335
references: Microbiol Immunol. 2002;46(12):881-3
references: 12597363
references: Drug Dev Ind Pharm. 2006 Feb;32(2):229-38
references: 16537203
references: Evid Based Complement Alternat Med. 2010 Sep;7(3):307-15
references: 18955317
references: Evid Based Complement Alternat Med. 2005 Mar;2(1):29-32
references: 15841275